Trial design, treatments, oversight and conduct
We administered atezolizumab, autogene cevumeran and mFOLFIRINOX sequentially to measure how each immunotherapy modulated neoantigen-specific T cells. To establish clinical feasibility, we set the following benchmarked times to treatment after surgery (Fig. We conducted the study in accordance with the Declaration of Helsinki and good clinical practice guidelines. The study was approved by the institutional review board at MSK, the US Food Drug Administration and was registered on ClinicalTrials.gov (